Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology

被引:33
|
作者
Hoyt, Clifford C. [1 ]
机构
[1] Akoya Biosci Inc, Malborough, MA USA
关键词
Predictive biomarkers; multiplex immunofluorescence; multispectral imaging; immuno-oncology; clinical workflow; image analysis; automated staining; spatial biology; LUNG-CANCER; EXPRESSION; ASSAY; IMMUNOHISTOCHEMISTRY; REPRODUCIBILITY; ASSOCIATION; NSCLC;
D O I
10.3389/fmolb.2021.674747
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As immuno-oncology (I/O) emerges as an effective approach in the fight against cancer, multispectral imaging of multiplex immunofluorescence (mIF) is maturing as an analytical platform. The timing is fortuitous. Due to health economic considerations surrounding the use of I/O, there is an urgent need for tests that accurately predict response to the growing list of available therapies. Multispectral mIF provides several advantages over other biomarker modalities by enabling deeper interrogation of the intricate biology within the tumor microenvironment, including detection of cell-to-cell spatial interactions that correlate with clinical outcomes. It also provides a practical path for generating reliable and reproducible results in a clinically suitable, high-throughput workflow. In this article, we (1) describe the principles behind multispectral mIF; (2) provide advice and recommendations on assay development and optimization and highlight characteristics of a well-performing assay; and (3) discuss the requirements for translating this approach into clinical practice.
引用
收藏
页数:14
相关论文
共 48 条
  • [41] Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
    Robert S. Seitz
    Michael E. Hurwitz
    Tyler J. Nielsen
    Daniel B. Bailey
    Matthew G. Varga
    Brian Z. Ring
    Carrie F. Metts
    Brock L. Schweitzer
    Kimberly McGregor
    Douglas T. Ross
    Journal of Translational Medicine, 20
  • [42] Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
    Seitz, Robert S.
    Hurwitz, Michael E.
    Nielsen, Tyler J.
    Bailey, Daniel B.
    Varga, Matthew G.
    Ring, Brian Z.
    Metts, Carrie F.
    Schweitzer, Brock L.
    McGregor, Kimberly
    Ross, Douglas T.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [43] Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate
    Evans, Catherine A.
    Liu, Tao
    Lescarbeau, Andre
    Nair, Somarajan J.
    Grenier, Louis
    Pradeilles, Johan A.
    Glenadel, Quentin
    Tibbitts, Thomas
    Rowley, Ann M.
    DiNitto, Jonathan P.
    Brophy, Erin E.
    O'Hearn, Erin L.
    Ali, Janid A.
    Winkler, David G.
    Goldstein, Stanley I.
    O'Heam, Patrick
    Martin, Christian M.
    Hoyt, Jennifer G.
    Soglia, John R.
    Cheung, Culver
    Pink, Melissa M.
    Proctor, Jennifer L.
    Palombella, Vito J.
    Tremblay, Martin R.
    Castro, Alfredo C.
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (09): : 862 - 867
  • [44] Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials
    Gan, Chun L.
    Stukalin, Igor
    Meyers, Daniel E.
    Dudani, Shaan
    Grosjean, Heidi A., I
    Dolter, Samantha
    Ewanchuk, Benjamin W.
    Goutam, Siddhartha
    Sander, Michael
    Wells, Connor
    Pabani, Aliyah
    Cheng, Tina
    Monzon, Jose
    Morris, Don
    Basappa, Naveen S.
    Pal, Sumanta K.
    Wood, Lori A.
    Donskov, Frede
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 115 - 125
  • [45] Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens
    Shi, Yang
    Ma, Xiaopeng
    Shen, Wei
    Liu, Tengfei
    Liang, Liang
    Liu, Silu
    Shen, Zhirong
    Zhang, Yun
    Zhang, Pei
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [46] Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study
    Bodd, Monica H.
    Locke, Susan C.
    Wolf, Steve P.
    Antonia, Scott
    Crawford, Jeffrey
    Hartman, John
    Herring, Kris W.
    Ready, Neal E.
    Stinchcombe, Thomas E.
    Troy, Jesse D.
    Williams, Chakita
    Clarke, Jeffrey M.
    LeBlanc, Thomas W.
    LUNG CANCER, 2023, 175 : 17 - 26
  • [47] Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy
    Goyal, Ravi K.
    Zhang, Jingchuan
    Davis, Keith L.
    Sluga-O'Callaghan, Martina
    Kaufman, Peter A.
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 855 - 865
  • [48] Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)
    Cheung, Carol C.
    Barnes, Penny
    Bigras, Gilbert
    Boerner, Scott
    Butany, Jagdish
    Calabrese, Fiorella
    Couture, Christian
    Deschenes, Jean
    El-Zimaity, Hala
    Fischer, Gabor
    Fiset, Pierre O.
    Garratt, John
    Geldenhuys, Laurette
    Gilks, C. Blake
    Ilie, Marius
    Ionescu, Diana
    Lim, Hyun J.
    Manning, Lisa
    Mansoor, Adnan
    Riddell, Robert
    Ross, Catherine
    Roy-Chowdhuri, Sinchita
    Spatz, Alan
    Swanson, Paul E.
    Tron, Victor A.
    Tsao, Ming-Sound
    Wang, Hangjun
    Xu, Zhaolin
    Torlakovic, Emina E.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (10) : 699 - 714